Listed by the USPTO as MEJIAS, SAMANTHA LEE
Tech Center 1600 • Art Units: 1618
This examiner grants 47% of resolved cases
MEJIAS, SAMANTHA LEE has 30 resolved cases in art unit 1618 and tech center 1600. The allowance rate is 46.7%, interview lift is 40.0%, and median time to allowance is 1432 days. The limited case volume calls for caution, but the available record shows outcomes below a majority allowance result and a substantial association between interviews and allowance. The median timing indicates lengthy prosecution.
The listed companies are The Regents of the University of California, Kyungpook National University Industry-Academic Cooperation Foundation, and The University of Hong Kong. The firms are Meunier Carlin & Curfman LLC, Casimir Jones, S.C., and FOLEY & LARDNER LLP. Applicants may benefit from early interview preparation, while retaining detailed fallback positions for a record where allowance is not the prevailing outcome.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18463384 | MEDICAL DEVICE OPERATION METHOD AND DRUG TREATMENT SUPPORT SYSTEM | Final Rejection | Canon Kabushiki Kaisha |
| 18834636 | THERAGNOSTIC FOLATE CONJUGATES | Non-Final OA | Merck Patent GmbH |
| 18119456 | FLUORINE-CONTAINING COMPOUND AND CONTRAST AGENT | Non-Final OA | TDK Corporation |
| 18731289 | Oxidative Cyclization Reagents for Chemoselective Tryptophan Bioconjugation | Non-Final OA | The Regents of the University of California |
| 17613351 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18276311 | LUNG LESION LOCALIZATION MULTI-IMAGING CONTRAST AGENT COMPOSITION FOR RESTRICTIVE LUNG RESECTION | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 17995024 | STABILIZER FOR RADIOPHARMACEUTICALS AND RADIOPHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Final Rejection | UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION |
| 18737027 | TRIPLET-TRIPLET ENERGY TRANSFER WITH LIGHT EXCITATION AT LONG WAVELENGTHS AND METHODS THEREOF | Non-Final OA | The University of Hong Kong |
| 18702650 | PHOTOCLEAVABLE PRODRUG-BASED NANOMEDICINE FOR IN-SITU MONITORABLE CANCER THERAPY | Non-Final OA | The University of Hong Kong |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy46.7% of resolved applications examined by Samantha Lee Mejias were allowed (30 resolved cases), compared with 33.1% across Art Unit 1618 over the last five years.
This examiner's interview lift is +40.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Samantha Lee Mejias took 1,432 days on average from filing to allowance.
Samantha Lee Mejias examines applications in Art Unit 1618 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
